Review paper
Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits

https://doi.org/10.1016/0267-6605(93)90017-2Get rights and content

Abstract

The use of devices which result in exposure of blood to artificial surface has gained increasing importance in routine medical and surgical practice. In the field of biocompatibility, attention has long been directed at the mechanisms of thrombus formation of surfaces. In recent years however, a special interest has emerged for the study of the imnumnlogical consequences of blood-artificial surface interactions, thus broadening the concept of hemocompatibility. The contact of blood with artifical devices results in the activation of a number of humoral and cellular processes involved in natural and in specific immunological recognition of foreign surfaces by the host, and in the secondary occurrence of acute and chronic adverse reactions in patients undergoing extracorporeal circulation.

The purpose of this review is to discuss the mechanisms involved in immunological bioincompatibility of extracorporeal circuits, with particular emphasis on the molecular basis of the activation of the complement system, the role of endotoxins, and the nduction of cytokine production by activated monocytes.

Reference (205)

  • AmadoriA. et al.

    Hemodialysis leukopenia and complement function with different dialyzers

    Kidney Int.

    (1983)
  • CheungA.K. et al.

    Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophane

    Kidney Int.

    (1990)
  • KirklinJ.K. et al.

    Complement and damaging effects of cardiopulmonary bypass

    J. Thorac. Cardiovasc. Surg.

    (1983)
  • KirklinJ.K. et al.

    Effects of protamine adminstration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state

    Ann. Thorac. Surg.

    (1986)
  • VidemV. et al.

    Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits

    J. Thorac. Cardiovasc. Surg.

    (1991)
  • HerbelinA. et al.

    Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α

    Kidney Int.

    (1990)
  • HerbelinA. et al.

    Elevated circulating levels of interleukin-6 in patients with chronic renal failure

    Kidney Int.

    (1991)
  • CavaillonJ-M. et al.

    Signals involved in IL-1 synthesis and release by LPS-stimulated monocyte/macrophages

    Cytokine.

    (1990)
  • AuronP.E. et al.

    The structure and regulation of the human prointerleukin-1 beta gene

    Ann. Inst. Pasteur Immunol.

    (1987)
  • CazenaveJ.P. et al.

    Blood-surface interactions

  • KinoshitaT.

    Overview of complement biology

    Immunol. Today

    (1991)
  • IsenmannD.E. et al.

    Nucleophilic modification of human complement protein C3: corre lation of conformational changes with acquisition of C3b-like functional properties

    Biochemistry

    (1981)
  • FarriesT.C. et al.

    Evolution of the complement system

    Immunol. Today

    (1991)
  • KazatchkineM.D. et al.

    The human alterantive complement pathway: biology and immunopathology of activation and regulation

    Progr. Allerg

    (1982)
  • CarrenoM.P. et al.

    Regulation of the human alternative complement pathway: formation of the ternary com plex between factor H surface-bound C3b and chemical groups on nonactivating surfaces

    Eur. J. Immunol.

    (1989)
  • Kazatchkine, M. D., Fearon, D. T., Silbert, J. E. & Austen, K. F., Surface associated heparin inhibits zymosan-induced...
  • ShenkeinH.A. et al.

    The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for zymosan enhances alternative pathway activation by zymosan

    J. Immunol.

    (1981)
  • MooreF.D. et al.

    IgG on mouse erythrocytes augments activation of the human alternative pathway by enhancing deposition of C3b

    J. Immunol.

    (1981)
  • Carreno, M. P., Maillet, F., Labarre, P., Jozefovicz, M. & Kazatchkine, M. D., Specific antibodies enhance...
  • MailletF. et al.

    Specific antibodies enhance alternative complement pathway activation by cuprophane

    Nephrol. Dial. Transplant.

    (1991)
  • Müller-EberhardH.J.

    Complement chemistry and pathways

  • FiedelB.A. et al.

    Complement activation by interaction of polyanions and polycations

    Immunology

    (1976)
  • Ahearn, J. M., Fearon, D. T., Structure and function of the complement receptors CR1 (CD35) and CR2 (CD21). Adv....
  • KlicksteinL.B. et al.

    Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis

    J. Exp. Med.

    (1988)
  • WeissL. et al.

    Regulation of the immune response by human C3 receptors

    Bailliére's Clin. Immuno. Allergy

    (1988)
  • WrightS.D. et al.

    Identification of the C3bi receptor of human monocytes and macrophages by using monoclonal antibodies

  • Sanchez MadridF. et al.

    A human leukocyte differentiation family with distinct alpha subunits and a common beta subunit: the lymphocyte function-associated antigen (LFA-1), the Obi complement receptor (OKMI/Mac1), and the p150,95 molecule

    J. Exp. Med.

    (1983)
  • MyonesB.L. et al.

    Neutrophil and monocyte cell surface p159,95 has iC3breceptor (CR4) activity resembling CR3

    J. Clin. Invest.

    (1988)
  • BergerM. et al.

    Human neutrophils increase expression of Obi as well as Cab receptors upon activation

    J. Clin. Invest

    (1984)
  • CouturierC. et al.

    Induction of cell-associated IL-1 through stimulation of the adhesion-promoting protein LFA-i (CDlla/CD18) and CR3 (CDllb/CD18) of human monocytes

    Eur. J. Immunol.

    (1990)
  • BhakdiS. et al.

    Relative inefficiency of terminal complement activation

    J. Immunol.

    (1988)
  • HughT.E. et al.

    Isolation of three separate anaphylatoxins from complement-activated human serum

    Mol. Cell. Biochem.

    (1981)
  • BokischV.A. et al.

    Anaphylatoxin inactivator of human plasma: its isolation and characterization as a car☐ypeptidase

    J. Clin. Invest.

    (1970)
  • VogtW.

    Possible roles of anaphylatoxins in disease

    Complement

    (1986)
  • CraddockP.R. et al.

    Complement (C5a)induced granuloctye aggregation in vitro: a possible mechanism for complement-mediated leukostasis and leukopenia

    J. Clin, Invest.

    (1977)
  • HughT.E.

    Biochemistry and biology of anaphylatoxins

    Complement

    (1986)
  • Haeffner-CavaillonN. et al.

    C3a/C3adesArg induces production and release of interleukin-1 by cultured human monocytes

    J. Immunol.

    (1987)
  • RollinsT.E. et al.

    Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex

  • ArnaoutM.A. et al.

    Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis

    New Engl. J. Med.

    (1985)
  • Cited by (37)

    • Blood compatibility of nanomaterials

      2018, Drug Delivery Nanosystems for Biomedical Applications
    • Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma

      2001, Biochimica et Biophysica Acta - Biomembranes
      Citation Excerpt :

      The other complement proteins investigated, i.e., factors B, H, and I were all depleted relative to plasma. This finding argues against significant complement activation since factor B is known to bind to C3 when activation occurs [41] so that factor B would be expected to be enriched on the liposome surface. The cell-adhesive proteins fibronectin and vitronectin were also investigated.

    • Clinical performance of a new high-flux synthetic membrane

      2000, American Journal of Kidney Diseases
      Citation Excerpt :

      Our study has shown minimal activation with both the materials studied, and the total absence of activation may be a consequence of surface interactions of other still unidentified factors with glycoproteins and phospholipids contained in the cell membrane. Complement activation induces interleukin-1 and tumor necrosis factor-α production in monocytes, which is enhanced in the presence of the small amounts of lipopolysaccharides known to be present in dialysis fluid.34,35 C5b-9 attacks such autologous nonnucleated cells as red blood cells and may contribute to the structural and functional erythrocyte changes seen in renal failure and the shortened erythrocyte survival times.36,37

    View all citing articles on Scopus
    View full text